FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| 5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial. PMID 41794436 · Lancet · 2026-Mar-07 The trial is a Phase 3 randomized trial in oncology (breast cancer) with a time-to-event primary endpoint (arm lymphoedema reported as HR), but the intervention is radiotherapy (radiation dose fractionation), not a drug. The criteria require a drug-containing intervention for eligibility. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. PMID 41793559 · Breast Cancer Res Treat · 2026-Mar-07 The study is an observational comparative effectiveness analysis using a target trial emulation framework on real-world data, not a report of an original Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention. It does not meet the criteria for a primary or secondary report of a definitive randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Prophylactic para-aortic irradiation vs pelvic radiotherapy in pelvic node-positive carcinoma cervix in the setting of concurrent chemoradiation: a phase II open-label multi centric randomized controlled trial (PRO-PARA). PMID 41792812 · Trials · 2026-Mar-07 The record describes a protocol for a Phase II/III randomized trial in cervical cancer with a drug (cisplatin) intervention. While it meets many inclusion criteria (oncology, human, randomized, phase 3, drug intervention), it is excluded because it is a protocol without reported results, and no time-to-event efficacy endpoint (e.g., OS, PFS) or survival analysis (Kaplan-Meier, HR) is described. The primary endpoint mentioned is 'demonstration of reduction in the risk of para-aortic recurrence,' but the abstract does not report any data, results, or confirm it as a time-to-event outcome suitable for KM digitization. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Vaccination against chikungunya - a systematic review on the immunogenicity, tolerability, and safety of the live-attenuated vaccine (LAV) Ixchiq and the virus like particle (VLP) vaccine Vimkunya. PMID 41564838 · Vaccine · 2026-Mar-07 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Safety, immunogenicity, and lot consistency of a 13-valent pneumococcal conjugate vaccine in Chinese children aged 2-5 years: A phase III study. PMID 41554243 · Vaccine · 2026-Mar-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Meningococcal quadrivalent ACYW-TT conjugated vaccine at 6-23 months: phase III study (US/Puerto Rico). PMID 41792337 · Pediatr Res · 2026-Mar-06 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Suzetrigine (a NaV1.8 inhibitor) versus placebo for acute postoperative pain: A systematic review and meta-analysis of randomized controlled trials. PMID 41790692 · Medicine (Baltimore) · 2026-Mar-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Inebilizumab treatment in Japanese patients with IgG4-related disease: a subgroup analysis of a randomized, double-blind, placebo-controlled, phase 3 trial (MITIGATE). PMID 41786624 · Mod Rheumatol · 2026-Mar-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis-Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation. PMID 41813432 · JMIR Res Protoc · 2026-Mar-05 This is a protocol for a randomized trial in multiple myeloma, but it is not Phase III/IIIb or Phase II/III, and it lacks primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Thermal ablation versus hepatectomy for solitary colorectal liver metastases up to 5 cm: a multicenter target trial emulation on safety, efficacy, and cost-effectiveness. PMID 41787469 · BMC Med · 2026-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Desidustat's Efficacy and Safety in Non-Dialysis Chronic Kidney Disease Patients with Anemia. PMID 41785204 · Am J Nephrol · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety of extending dosing intervals of denosumab in adults with solid cancer and bone metastasis: a review. PMID 41785076 · Br J Nurs · 2026-Mar-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| AI-Driven Analysis of Cardiopulmonary Exercise Tests to Identify Gas Exchange and Ventilatory Thresholds. PMID 41784915 · Sports Med · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical evaluation of the efficacy and safety of nasturtium herb and horseradish root versus placebo in the continuous prophylaxis of recurrent uncomplicated cystitis: a double-blind randomised clinical trial. PMID 41782129 · BMC Complement Med Ther · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Finerenone in Type 1 Diabetes and Chronic Kidney Disease. PMID 41780000 · N Engl J Med · 2026-Mar-05 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). PMID 40884070 · Eur Heart J · 2026-Mar-05 The trial is a randomized, double-blind, placebo-controlled study in advanced cancer patients, but the primary endpoint is a composite of functional/well-being measures, not a time-to-event efficacy endpoint. Mortality is mentioned as a secondary safety measure, not as a primary or key secondary time-to-event endpoint for efficacy analysis. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Somapacitan in children born small for gestational age: a randomized controlled phase 3 trial. PMID 41782416 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Can topical coconut oil reduce late-onset sepsis in extremely preterm infants? A pragmatic cluster-randomised controlled trial protocol. PMID 41781050 · BMJ Open · 2026-Mar-04 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. PMID 41781018 · J Immunother Cancer · 2026-Mar-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Lepodisiran: An Updated Review on a Novel and Emerging Lipoprotein (a) Lowering Agent. PMID 41779052 · Cardiol Rev · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness of transversus abdominis plane block versus local anaesthesia wound infiltration for postoperative pain relief after laparoscopic appendicectomy in children: A multicentre, double-blind, randomised, controlled phase III trial. PMID 41777031 · Eur J Anaesthesiol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial. PMID 41774755 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. PMID 41586496 · Antimicrob Agents Chemother · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. PMID 41832961 · JNCI Cancer Spectr · 2026-Mar-03 The record describes a randomized trial with drug intervention and time-to-event endpoints. However, the formal trial phase (Phase III, IIIb, or II/III) is not explicitly stated in the provided metadata (title, abstract, publication types, or MeSH). The deterministic review also flagged 'phase3_evidence_unclear'. Without explicit phase information, eligibility cannot be definitively established. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. PMID 41774854 · Blood Adv · 2026-Mar-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer. PMID 41774617 · Urol Int · 2026-Mar-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Potential bias in the clinical trial registration of patients with peripheral small-sized non-small cell lung cancer: Real-world data in the era of segmentectomy. PMID 41774196 · Surg Today · 2026-Mar-03 The record describes an observational study analyzing patient selection and registration bias related to the JCOG0802/WJOG4607L trial. It is not a report of a randomized clinical trial with a drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study. PMID 41592243 · JNCI Cancer Spectr · 2026-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. PMID 41493295 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. PMID 41348072 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer. PMID 41915394 · JAMA Netw Open · 2026-Mar-02 The record is an original analysis from a large randomized trial (NLST). However, it is not eligible because it is a screening/diagnostic study, not a therapeutic trial. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. PMID 41915391 · JAMA Netw Open · 2026-Mar-02 The record reports a randomized clinical trial in oncology with primary time-to-event endpoints (OS, PFS) and a drug-containing intervention. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, making it impossible to confirm eligibility under the strict criterion requiring explicit phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 41893843 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. PMID 41885866 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bayesian Statistics to Reanalyze Data From the STAAMP Trial. PMID 41842893 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis. PMID 41827741 · Cancers (Basel) · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. PMID 41817524 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. PMID 41811317 · JAMA Netw Open · 2026-Mar-02 The study is a randomized controlled trial of sivelestat vs placebo in cardiovascular surgery patients, reporting on ARDS incidence and 90-day mortality. While it includes a time-to-event outcome (mortality), it is not an oncology study (ARDS is not a human malignant neoplasm). The trial is not identified as Phase III/IIIb or a definitive oncologic trial. Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival. PMID 41790469 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Key considerations for safe de-escalation of therapy for POLE mutated endometrial cancer. PMID 41775567 · Int J Gynecol Cancer · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Correction: Psychometric evaluation of a pediatric functional constipation symptom diary using randomized phase 3 clinical trial data. PMID 41770459 · J Patient Rep Outcomes · 2026-Mar-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial Links Time of Day to Immunotherapy Success. PMID 41632563 · Cancer Discov · 2026-Mar-02 The record is a news article reporting on a randomized trial, but the abstract lacks explicit details on the trial phase, a specific time-to-event primary/key secondary endpoint, or statistical results like Kaplan-Meier or HR. Therefore, key eligibility criteria cannot be confidently established from the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect Modification by Serum Vitamin A Levels on the Association between Vitamin D and Relapse or Death in Patients with Digestive Tract Cancer. PMID 41524587 · Cancer Epidemiol Biomarkers Prev · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial. PMID 41504649 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer. PMID 41489691 · Clin Cancer Res · 2026-Mar-02 The record is from a randomized oncology trial with drug intervention and time-to-event endpoints. However, the explicit phase (III/IIIb or II/III) is not confirmed in the provided metadata. Per instructions, the phase cannot be inferred. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial. PMID 41427962 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. PMID 41405563 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer. PMID 41385615 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The 3-Year Results of a 100-Patient Prospective Study of the Safety and Effectiveness of Mia Femtech. PMID 41052824 · Aesthet Surg J · 2026-Mar-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial: Erratum. PMID 41859871 · J Chin Med Assoc · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |